Announcement
10 Oct 2025
In October 2025, the United States of America announced an agreement with AstraZeneca to implement most-favoured-nation drug pricing for America patients. The agreement also includes a three-year delay on Section 232 tariffs for AstraZeneca.
Source
Sign in to access
Number of interventions
3
0 certainly harmful
3 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 13 Oct 2025
Local operations incentive
On 10 October 2025, the United States announced a deal with AstraZeneca. Under the deal, the U.S. Department of Commerce will delay the implementation of Section 232 tariffs on pharmaceutical products...
Sign in to see more
Updated: 13 Oct 2025
Tax or social insurance relief
On 10 October 2025, the United States announced reaching an agreement with AstraZeneca. Under the agreement, AstraZeneca will be exempt from future Section 232 tariffs on pharmaceutical products for t...
Sign in to see more
Updated: 13 Oct 2025
Import tariff
On 10 October 2025, the United States announced an agreement with AstraZeneca granting the company a three-year grace period from Section 232 pharmaceutical tariffs. In exchange for this exemption, As...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.